Hemostemix Inc. (CVE:HEM – Get Free Report) shares crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$0.09 and traded as low as C$0.09. Hemostemix shares last traded at C$0.09, with a volume of 42,774 shares.
Hemostemix Stock Performance
The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The firm has a 50 day moving average price of C$0.09 and a two-hundred day moving average price of C$0.10. The company has a market capitalization of C$16.96 million, a P/E ratio of -3.33 and a beta of 1.25.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Further Reading
- Five stocks we like better than Hemostemix
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
